These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 18422070)

  • 1. [Treatment of hematologic neoplasms during pregnancy].
    Tartas NE; Foncuberta MC; Avalos JC
    Medicina (B Aires); 2007; 67(6 Pt 2):729-36. PubMed ID: 18422070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CML: imatinib mesylate (Glivec) or something else?
    Ghosh A
    Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
    [No Abstract]   [Full Text] [Related]  

  • 3. Twin pregnancy in a patient of chronic myeloid leukemia on imatinib therapy.
    Meera V; Jijina F; Shrikande M; Madkaikar M; Ghosh K
    Leuk Res; 2008 Oct; 32(10):1620-2. PubMed ID: 18420270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pregnancy complicated with chronic myelogeneous leukemia (CML) successfully treated with imatinib: a case report.
    Buyukbayrak EE; Ergen B; Karsidag YK; Kars B; Turan C; Argon D
    Arch Gynecol Obstet; 2008 Aug; 278(2):161-3. PubMed ID: 18193246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular target therapy in hematological malignancy: front-runners and prototypes of small molecule and antibody therapy.
    Kobayashi Y
    Jpn J Clin Oncol; 2011 Feb; 41(2):157-64. PubMed ID: 21113055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of molecular remission throughout pregnancy in CML after imatinib.
    Sorà F; De Matteis S; Bajer J; D'alò F; Leone G; Sica S
    Leuk Res; 2009 Jun; 33(6):e6-7. PubMed ID: 18937976
    [No Abstract]   [Full Text] [Related]  

  • 8. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
    Potenza L; Volzone F; Riva G; Soverini S; Martinelli S; Iacobucci I; Gnani A; Barozzi P; Forghieri F; Morselli M; Zanetti E; Maccaferri M; Baccarani M; Martinelli G; Torelli G; Luppi M
    Br J Haematol; 2009 Jul; 146(2):227-30. PubMed ID: 19545285
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pharmacogenetics and tailored drug therapy].
    Nielsen FC; Borregaard N
    Ugeskr Laeger; 2009 Mar; 171(10):790-4. PubMed ID: 19265602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic molecular marker and molecular targeted-therapy in pediatric malignancies].
    Hayashi Y
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):194-202. PubMed ID: 17301526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hematologic neoplasms and pregnancy].
    Tartas N; Chacón R; Sánchez Avalos JC
    Medicina (B Aires); 1995; 55(2):155-8. PubMed ID: 7565054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib resistance in CML.
    Volpe G; Panuzzo C; Ulisciani S; Cilloni D
    Cancer Lett; 2009 Feb; 274(1):1-9. PubMed ID: 18653275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor.
    Inokura K; Onishi Y; Shimosegawa K; Okitsu Y; Katsuoka Y; Fujiwara T; Fukuhara N; Ishizawa K; Harigae H
    Ann Hematol; 2012 Nov; 91(11):1825-6. PubMed ID: 22543830
    [No Abstract]   [Full Text] [Related]  

  • 14. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
    Chien JH; Tang JL; Chen RL; Li CC; Lee CP
    Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate for the treatment of chronic myeloid leukemia.
    Soverini S; Martinelli G; Iacobucci I; Baccarani M
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):853-64. PubMed ID: 18533795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Hwang YY; Tse E; So JC; Wan TS; Kwong YL
    Am J Hematol; 2009 May; 84(5):302-5. PubMed ID: 19338042
    [No Abstract]   [Full Text] [Related]  

  • 17. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
    Tanaka R; Kimura S
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCR-ABL in chronic myelogenous leukemia--how does it work?
    Goldman JM; Melo JV
    Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Detection of ABL kinase domain point mutations in chronic myeloid leukemia patients receiving imatinib treatment].
    Ouyang Z; DU QF; Liu XL; Zhang S; Zhu HQ; Gong JM; Song LL; Ouyang LY; Liu Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):704-6. PubMed ID: 18504184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism.
    Breccia M; Alimena G
    Leuk Res; 2009 Jul; 33(7):871-5. PubMed ID: 19307018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.